| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_75340acb75e7522ea270faf62d315b4a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a7b56f8e9a6b41d26bfb8f3da696c09d |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2730-10122 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6876
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-51
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-02 |
| filingDate |
2005-06-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2008-06-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6d6a58a9910a2c394a9cc3fbd5882329
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dc4ffc7c1ab0bf1f0a0b50941b8106e9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d4a886f347ee81cde54be9ad2a257c84
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d258b891942af1c8fb8a8d2a982ab53c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e42213f6e0d0ceb2625d95c627498335
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_91b55c5d8d2c40dd9b6a3c0f5128d8f0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d6347ab5fc9247b89171be06525a3e23 |
| publicationDate |
2008-06-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-7384747-B2 |
| titleOfInvention |
Hepatitis B viral variants with reduced susceptibility to nucleoside analogs and uses thereof |
| abstract |
The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for and/or develop or design agents capable of inhibiting infection, replication and/or release of the virus. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8859198-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2014199268-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2010203506-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9682109-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9932646-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9701982-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9702005-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2010075299-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2008274083-A1 |
| priorityDate |
2002-04-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |